Skip to main content

The impact of CYP2C19 *2 and *3 polymorphism on clopidogrel response following coronary stenting in Saudi patients with acute coronary syndrome

Background

Clopidogrel is a widely used oral, antiplatelet agent of thienopyridine class used to inhibit thrombosis following drug eluting stent (DES) placement [1]. The variability of response (platelet function testing) to clopidogrel is multifactorial and genetic polymorphism has been known to be the main cause [2].

Materials and methods

Ninety Saudi patients with acute coronary syndrome who underwent coronary angioplasty with drug eluting stents were consecutively enrolled in Prince Sultan Cardiac Center, Buraidah. Patients received clopidogrel as per usual dose of 300mg loading (about 4 days prior to procedure) and 75mg per day as maintenance dose. Two blood samples were withdrawn from each patient. DNA was extracted by [MagNAPure LC,Roche, Germany]. CYP2C19 and Genotyping for *1, *2 and *3 was conducted by real-time PCR [Roche Molecular Biochemicals, Mannheim, Germany]. Platelet function testing was carried out using (Verify Now P2Y12) and all the in-hospital clinical events were monitored for patients.

Results

Sixty (66.7%) patients have the genotype 1/1, 28 (31.1%) patients have 2/2 and 2 (2.2%) have1/2 genotype. There was no significant difference in mean P2Y12 reaction units (PRU) of patients with wild variant and resistant variant (193±76u vs.212± 55.4 p value=0.349). The mean percentage of inhibition also did not differ significantly in the two groups (16.9±15.5 for wild variant and 9.4 for resistant variant P value= 0.135). One in-hospital clinical event (in-stent thrombosis) was encountered and thus was too rare for any significant comparison.

Conclusions

In this study genotyping revealed polymorphism but we found no impact of the polymorphism on the percentage of platelet inhibition following four days of clopidogrel ingestion.

References

  1. 1.

    Mehta SR, Yusuf S, Peters RJ, et al: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoingpercutaneous coronary intervention: the PCI-CURE study. Lancet. 2001, 358: 527-533.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Mega JL, Close SL, Wiviott SD, et al: Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009, 360: 354-362.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Al Meman A.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

H, K., A, A.M. & S, R. The impact of CYP2C19 *2 and *3 polymorphism on clopidogrel response following coronary stenting in Saudi patients with acute coronary syndrome. BMC Genomics 15, P26 (2014). https://doi.org/10.1186/1471-2164-15-S2-P26

Download citation

Keywords

  • Acute Coronary Syndrome
  • Clopidogrel
  • Antiplatelet Agent
  • Drug Elute Stent
  • Platelet Inhibition